Literature DB >> 573892

Intercalative binding to DNA of antitumour drugs derived from 3-nitro-1,8-naphthalic acid.

M J Waring, A González, A Jiménez, D Vázquez.   

Abstract

Two new antitumour drugs, imide derivatives of 3-nitro-1,8-naphthalic acid having different basic side chains linked to the imide nitrogen, have been shown to bind to double-helical DNA by intercalation. At ionic strength 0.01 mol/litre, pH 7, their intrinsic association constants are about 1.45 x 10(5) M-1 and each bound ligand molecule occludes about 3.4 nucleotides of the DNA lattice. They remove and reverse the supercoiling of closed circular duplex PM2 DNA with apparent unwinding angles of 11-12 degrees per bound drug molecule, referred to an assumed unwinding angle of 26 degrees for ethidium. They increase the viscosity of sonicated rod-like DNA fragments, each bound drug molecule producing a calculated increment in length of 2.2 - 2.5 A. No important differences between the DNA-binding characteristics of the two drugs were detected, though one appears marginally more active than the other in certain biological tests.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 573892      PMCID: PMC328007          DOI: 10.1093/nar/7.1.217

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  22 in total

1.  DNA-binding characteristics of acridinylmethanesulphonanilide drugs: comparison with antitumour properties.

Authors:  M J Waring
Journal:  Eur J Cancer       Date:  1976-12       Impact factor: 9.162

2.  TUMOR INHIBITORS. I. ARISTOLOCHIC ACID, THE ACTIVE PRINCIPLE OF ARISTOLOCHIA INDICA.

Authors:  S M KUPCHAN; R W DOSKOTCH
Journal:  J Med Pharm Chem       Date:  1962-05

3.  SPECTROPHOTOMETRIC STUDIES OF THE INTERACTION OF CHLOROQUINE WITH DEOXYRIBONUCLEIC ACID.

Authors:  S N COHEN; K L YIELDING
Journal:  J Biol Chem       Date:  1965-07       Impact factor: 5.157

4.  Influence of tilorone and cogeners on the secondary structure and template activity of DNA.

Authors:  P Chandra; M Woltersdorf
Journal:  FEBS Lett       Date:  1974-04-15       Impact factor: 4.124

5.  Echinomycin: a bifunctional intercalating antibiotic.

Authors:  M J Waring; L P Wakelin
Journal:  Nature       Date:  1974-12-20       Impact factor: 49.962

6.  Calculation of binding isotherms for heterogenous polymers.

Authors:  D M Crothers
Journal:  Biopolymers       Date:  1968-04       Impact factor: 2.505

7.  Transient electric dichroism studies of the structure of the DNA complex with intercalated drugs.

Authors:  M Hogan; N Dattagupta; D M Crothers
Journal:  Biochemistry       Date:  1979-01-23       Impact factor: 3.162

8.  Structural limitations on the bifunctional intercalation of diacridines into DNA.

Authors:  L P Wakelin; M Romanos; T K Chen; D Glaubiger; E S Canellakis; M J Waring
Journal:  Biochemistry       Date:  1978-11-14       Impact factor: 3.162

9.  Interaction of phenosafranine with nucleic acids and model polyphosphates. II. Characterisation of phenosafranine binding to DNA.

Authors:  Z Balcarová; V Kleinwächter; J Koudelka
Journal:  Biophys Chem       Date:  1978-03       Impact factor: 2.352

10.  The binding of echinomycin to deoxyribonucleic acid.

Authors:  S P Wakelin; M J Waring
Journal:  Biochem J       Date:  1976-09-01       Impact factor: 3.857

View more
  15 in total

1.  Computer simulation of the binding of amonafide and azonafide to DNA.

Authors:  S Bear; W A Remers
Journal:  J Comput Aided Mol Des       Date:  1996-04       Impact factor: 3.686

2.  Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study.

Authors:  Sarah A Taylor; Cathryn Rankin; Jeannette J Townsend; Johnny B Craig; Ralph B Vance; Dilip L Solank; Thomas D Brown; Kurt Jaeckle
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

3.  Phase I study of mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity.

Authors:  E Díaz-Rubio; M Martín; J M López-Vega; A Casado; A Benavides
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

4.  Imide derivatives of 3-nitro-1.8-naphthalic acid: their inhibitory activity against DNA viruses.

Authors:  A Garcá Gancedo; C Gil-Fernández; P Vilas; S Perez; E Paez; F Rodriguez; M F Braña; C M Roldán
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

5.  Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer.

Authors:  R Rosell; J Carles; A Abad; N Ribelles; A Barnadas; A Benavides; M Martin
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

6.  In vitro activity of amonafide against primary human tumors compared with the activity of standard agents.

Authors:  J A Ajani; F L Baker; G Spitzer
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

7.  Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study.

Authors:  C S Higano; P Goodman; J B Craig; J A Kish; S E Rivkin; M Wolf; E D Crawford
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

8.  Phase II study of amonafide in advanced pancreatic adenocarcinoma.

Authors:  K Linke; R Pazdur; J L Abbruzzese; J A Ajani; R Winn; J E Bradof; K Daugherty; B Levin
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

9.  Binding of quinoline analogues of echinomycin to deoxyribonucleic acid. Role of the chromophores.

Authors:  K R Fox; D Gauvreau; D C Goodwin; M J Waring
Journal:  Biochem J       Date:  1980-12-01       Impact factor: 3.857

10.  The pharmacokinetics, tissue distribution, and biotransformation of a new class of antitumor agents: mitonafide and pinafide.

Authors:  P Rivera Cid; E Gonzalez Fernandez; F R Martin; M F Braña
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Oct-Dec       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.